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Abstract
It has been proposed that either excessive inﬂammation or an imbalance in angiogenic factors cause
pre-eclampsia. In the present review, the arguments for and against the role of inﬂammation and/or
angiogenic imbalance as the cause of pre-eclampsia are discussed on the basis of the Bradford–Hill criteria
for disease causation. Although both angiogenic imbalance and systemic inﬂammation are implicated in
pre-eclampsia, the absence of temporality of inﬂammatory markers with pre-eclampsia challenges the
concept that excessive inﬂammation is the cause of pre-eclampsia. In contrast, the elevation of anti-
angiogenic factors that precede the clinical signs of pre-eclampsia fulﬁls the criterion of temporality. The
second most important criterion is the dose–response relationship. Although such a relationship has not
been proven between pro-inﬂammatory cytokines and pre-eclampsia, high levels of anti-angiogenic factors
have been shown to correlate with increased incidence and disease severity, hence satisfying this condition.
Finally, as the removal of circulating sFlt-1 (soluble Fms-like tyrosine kinase receptor-1) from pre-eclamptic
patients signiﬁcantly improves the clinical outcome, it fulﬁls the Hill’s experiment principle, which states
that removal of the cause by an appropriate experimental regimen should ameliorate the condition. In
contrast, treatment with high doses of corticosteroid fails to improve maternal outcome in pre-eclampsia,
despite suppressing inﬂammation. Inﬂammation may enhance the pathology induced by the imbalance in
the angiogenic factors, but does not by itself cause pre-eclampsia. Development of therapies based on the
angiogenic and cytoprotective mechanisms seems more promising.
Background
Pre-eclampsia is an important cause of maternal and perinatal
mortality affecting 5–7% of pregnant women [1]. Clinically,
it is defined as the de novo onset of hypertension (systolic
blood pressure  140 mmHg or diastolic blood pressure
 90 mmHg) and proteinuria ( 300 mg/24 h) after 20 weeks
of gestation. In extreme cases, serious complications of pre-
eclampsia can include acute renal failure, seizures (eclampsia),
pulmonary oedema, acute liver injury, haemolysis and/or
thrombocytopenia. The last three signs occur together as
part of the HELLP (haemolysis, elevated liver enzymes and
low platelets) syndrome, a severe variant of pre-eclampsia.
Apart from the hypertension and proteinuria, the central
nervous system also plays a role, such as headache and
hyperrelexia.
Pre-eclampsia has been cited as “the disease of the-
ories” because of its unknown aetiology [2]. In recent
years, endothelial dysfunction has emerged as the leading
phenomenon responsible for the clinical signs of the
disorder [3]. Endothelial dysfunction is commonly linked
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to the impairment of the NO (nitric oxide) pathway and
decrease in NO bioavailability [4,5]. Factors proposed
to cause endothelial dysfunction in pre-eclampsia include
poor placental vascular remodelling and placental ischaemia,
oxidative stress [6,7], excessive inflammation [8], imbalance
in angiogenic factors [9–12] and the loss of endogenous
protective regulators [3,13–15].
Poor placentation and reduction in uterine blood flow
(placental ischaemia) has for a long time been proposed
to be the leading cause for the increase in oxidative and
endoplasmic reticulum stress, production of potent pro-
inflammatory mediators and anti-angiogenic factors in pre-
eclampsia [16,17]. However, the role of inadequate placental
vascular remodelling due to defective trophoblast invasion
as the leading cause of pre-eclampsia has been disputed on
the basis of evidence that failure to remodel the uterine
arteries is also associatedwith intrauterine growth restriction,
where no signs of hypertension and proteinuria are observed
[18].
More recently, the ‘excessive inflammation’ and the
‘angiogenic imbalance’ theories were highlighted as the cause
of pre-eclampsia. Although a generalized systemic inflam-
mation is common to all pregnancies [19], Redman et al. [8]
proposed that pre-eclampsia is not intrinsically different from
normal pregnancy, but it is at the extreme end of a continuous
spectrum of inflammatory responses that are a feature of
pregnancy itself. In parallel, Ahmed [9] had proposed that
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Table 1 Bradford–Hill criteria of causation
Criterion Explanation
Temporality Exposure always precedes the outcome
Dose-response Increasing amount of exposure increases the risk
Experiment The condition can be altered (prevented or
ameliorated) by an appropriate experimental
regimen
Strength The stronger the association, the more likely it is
that the relationship of ‘A’ to ‘B’ is causal
Consistency The association is consistent when results are
replicated in studies in different settings using
different methods
Speciﬁcity When a single putative cause produces a speciﬁc
effect
Coherence The association should be compatible with existing
theory and knowledge
Plausibility There needs to be some theoretical basis for
positing an association between a vector and
disease
it is the imbalance in angiogenic factors that cause pre-
eclampsia; in particular, the increase in sFlt-1 (soluble Fms-
like tyrosine kinase receptor-1) and sEng (soluble endoglin)
and the decrease in PlGF (placenta growth factor). In the
present review, the arguments for the role of inflammation
and angiogenic imbalance as the cause of pre-eclampsia are
discussed on the basis of the Bradford–Hill criteria for disease
causation (Table 1).
Evidence of the role of angiogenic factors
in pre-eclampsia
In 1997, the angiogenic imbalance hypothesis proposed
that pre-eclampsia arises due to loss of VEGF (vascular
endoethlial growth factor) activity as a result of rise in sFlt-
1 [9]. This gained support when it was shown that sFlt-1
levels increased in the amniotic fluid [20] and placenta
[21] of pre-eclamptic women. The role of sFlt-1 in the
aetiology of pre-eclampsia acquired serious recognitionwhen
it was shown that adenoviral overexpression of sFlt-1 in
pregnant rats mimicked the clinical manifestations of pre-
eclampsia [10]. Indeed, anti-VEGF therapy also promotes
hypertension and proteinuria in cancer patients [22]. Further-
more, the circulating level of maternal sFlt-1 is significantly
elevated before the onset of the disorder and persisted until
delivery [23]. High levels of sFlt-1 causes endothelial dys-
function [10,24,25] and inhibits angiogenesis [26,27] by bind-
ing to and antagonizing the function of both VEGF and PlGF
[28]. In addition, the circulating levels of VEGF and
PlGF are decreased before the onset of pre-eclampsia [12,29].
Both VEGF [30,31] and PlGF [32] have been shown to
stimulate NO release [33], indicating that their loss would
lead to a reduction in NO production. Like sFlt-1, sEng is
elevated early in pre-eclampsia [11] and limits the activity of
TGFβ1 (transforming growth factorβ1) signalling and eNOS
(endothelial nitric oxide synthase) [34,35], hence promoting
vascular dysfunction and inhibiting angiogenesis [11].
Evidence of inﬂammation in pre-eclampsia
Both observational and experimental studies have demon-
strated an association between inflammation and endothelial
dysfunction [36,37]. Redman et al. [8] first proposed that pre-
eclampsia arises as a result of an excessive maternal intravas-
cular inflammatory response to pregnancy, which may occur
because either the stimulus or the maternal response is too
strong and involves both the innate and the adaptive immune
system. Two decades ago, Greer et al. [38] first showed that
neutrophil activation is confined to the maternal circulation
in pregnancy-induced hypertension, where it may contribute
to vascular damage. Soluble markers of neutrophil activation,
released in the circulation from the degranulation of activated
neutrophils, are also increased in pre-eclamptic patients. [39–
42]. Further evidence of enhanced inflammation in pre-
eclampsia has been demonstrated through the uncontrolled
increased activation of the complement system compared
with normal pregnancy. Activation of the complement
system amplifies inflammation, promotes chemotaxis of
inflammatory cells and generates proteolytic fragments that
enhance phagocytosis by neutrophils and monocytes [43].
Another important feature of systemic inflammation in
pre-eclampsia is the predominance of Th1-type immunity
and the absence of Th2 tendency. T-cells may be classified as
Th1 cells, which synthesize IL (interleukin)-2, IL-12, IFNγ
(interferon γ ) and TNFα (tumour necrosis factor α), and
induce cellular immunity, or Th2 cells, which synthesize IL-
4, IL-5, IL-6 and IL-10, and induce antibody production
[44]. Normal pregnancy is characterized by a shift towards
Th2-type immunity and the inhibition of cytotoxic Th1
immune responses, which could be harmful to the fetus
[45]. In pre-eclamptic patients, the decidual lymphocytes and
peripheral blood mononuclear cells are generally primed to
synthesize high levels of Th1 cytokines. In contrast, the same
patients exhibited low spontaneous or phytohaemagglutinin-
induced expression of the Th2 cytokines [46–48]. In addition,
circulating levels of pro-inflammatory cytokines such as IL-
6, TNFα and the chemokines IL-8, IP-10 (IFNγ -inducible
protein 10) and MCP-1 (monocyte chemoattractant protein
1) are also elevated in pre-eclampsia [49].
Inﬂammation compared with angiogenic
imbalance hypothesis
Temporal relationship
According to Hill [50], causation can be determined using
the temporal relationship, which implies that the cause of a
disorder must precede its clinical signs. Numerous studies
have shown that maternal circulatory sFlt-1 is elevated
as early as 5–10 weeks before the onset of pre-eclampsia
[23,51,52] and sEng is elevated as early as 11–13 weeks of
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gestation before the development of pre-eclampsia [53–58].
Furthermore, a decrease in urinary PlGF also precedes the
onset of pre-eclampsia [12]. Collectively, these observations
provide evidence of the cause and effect relationship between
the angiogenic imbalance theory and pre-eclampsia.
In contrast, neutrophil activation [38,59] and elevation
of Th1 pro-inflammatory cytokines [49,60–62] have been
shown to occur at the time of diagnosis of pre-eclampsia.
In addition, a prospective nested case control study and a
longitudinal study revealed that, at 18 weeks of gestation,
the levels of inflammatory parameters including TNFα, IL-6
and IFNγ were not elevated in women who later developed
pre-eclampsia compared with healthy controls [63,64]. The
lack of a temporal relationship between the inflammatory
cytokines and the maternal syndrome of pre-eclampsia puts
into question the long-held concept that pre-eclampsia is
caused by ‘excessive inflammation’.
Interestingly, the study by Lynch et al. [65] suggested
that early activation of the complement system in pregnancy
elevates the concentrations of circulating complement-
activated fragment Bb that could be associated with the
subsequent development of pre-eclampsia, independent of
the release of anti-angiogenic factors [43]. However, given
the heterogeneous nature of pre-eclampsia and the small
number of pre-eclamptic patients in this study (32 patients
who developed pre-eclampsia), additional studies are needed
to evaluate the relative implications of complement activation
in the pathogenesis of pre-eclampsia.
Strength of association and consistency
Compelling and consistent data from clinical studies
conducted in various centres have confirmed that circulating
levels of sFlt-1, sEng and PlGF gave the highest strength of
association with the clinical manifestation of early-onset pre-
eclampsia, satisfying the two criteria of causation: strength
of association between the cause and the disease and the
consistency of association in different settings [23,51,66,67].
In contrast, clinical data vary greatly with respect to
differences in specific level of inflammatory cytokines
between normal pregnant women and pre-eclamptic women.
Jonsson et al. [68] examined serum levels of 20 different
cytokines and found significant differences in only two, IL-
6 and IL-8, between pre-eclamptic and normal pregnant
women. Sharma et al. [69] observed similar increase in serum
IL-6 and IL-8 levels, but also found a significant increase
in serum TNFα and a decrease in IL-10 in pre-eclamptic
pregnant women compared with normal pregnant women.
Additional studies have found increases in placental and/or
peripheral blood levels of the inflammatory cytokines IL-
2, IL-12, IL-15, IL-18 and IFNγ in pre-eclamptic pregnant
women [69–71]. In contrast, Freeman et al. [72] observed
that the serum levels of IL-10 and TNFα are increased from
the first to the third trimester in healthy control pregnancies
to nearly the same degree as in women with pre-eclampsia
[72]. The inconclusive and contradictory findings about the
inflammatory cytokines challenge the role of inflammation
as the main cause of pre-eclampsia. Furthermore, with the
exception of a few studies [73,74], many studies have failed to
find a strong and consistent strength of association between
the increase in inflammatory status and the clinical signs of
pre-eclampsia, weakening the role of inflammation as the
cause of pre-eclampsia.
Dose–response relationship
To date, the only cure for pre-eclampsia is the delivery of
the baby and the removal of the placenta. Pre-eclampsia also
occurs in molar pregnancies (absence of fetus), indicating
that it is the placenta and not the fetus that causes the
condition. Increase in placental mass, as in singletons to
twins, triplets and quadruplets, also increases the incidence
of pre-eclampsia. In twin pregnancies, a 2-fold increase
in the level of sFlt-1 and an increase in the sFlt-1/PlGF
ratio were observed [75]. In a secondary analysis of the
NICHD (National Institute of Child Health and Human
Development) MFMU (Maternal–Fetal Medicine Unit) trial
of aspirin to prevent pre-eclampsia in high-risk pregnancies,
the odds of developing pre-eclampsia were significantly
increased among women with multiple placenta for each
2-fold elevation in sFlt-1, sEng and the ratio of angiogenic
factors, and significantly decreased for each 2-fold elevation
in circulating PlGF between 7 and 26 weeks of gestation [76].
Importantly, the fractional excretion of angiogenic factors
was significantly higher in women with severe pre-eclampsia
compared with those with mild pre-eclampsia or pregnant
controls [77], demonstrating that the increase in sFlt-1 is
directly proportional to the severity of the disorder. It is
also worth noting that sFlt-1 can only induce hypertension
and proteinuria in mice when its levels reach above a certain
critical threshold [24], supporting the theory that women
with fetal growth restriction, despite having elevated levels
of sFlt-1 compared with controls, do not exhibit signs
of hypertension or proteinurea [78]. These studies clearly
demonstrate the dose–response relationship between the level
of anti-angiogenic factors and the incidence and severity of
pre-eclampsia. To our knowledge, such a relationship has not
been established between pro-inflammatory cytokines and
pre-eclampsia.
Speciﬁcity and experiment
Animal studies provide strong evidence linking sFlt-1 and
sEng to the pathogenesis of pre-eclampsia [10,11,25,79–
86]. In pregnant rats, sEng acts synergistically with sFlt-
1 to induce endothelial dysfunction, hypertension, severe
proteinuria and HELLP syndrome [11]. Furthermore,
neutralizationof sFlt-1 belowa critical thresholdusingVEGF
eliminates the signs of pre-eclampsia in mice [24,84]. In
addition, Ahmad and Ahmed [26] showed previously that
immunoprecipitation of sFlt-1 from placental conditioned
medium of pre-eclamptic women restored angiogenesis as
demonstrated by in vitro tube formation. Following on from
this concept, recently, an elegant study by Thadhani et al.
[87] showed that the extractions of sFlt-1 from the plasma
of pre-eclamptic patients by apheresis (using a negatively
charged dextran sulfate cellulose column to which positively
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charged sFlt-1 is adsorbed), resulted in an approximate 35%
reduction in circulating sFlt-1. As a consequence, this was
accompanied by a reduction and stabilization of maternal
blood pressure leading to an increase in gestational age in
two patients by 16 days (for singleton pregnancy) and 19 days
(twin pregnancy) respectively. Collectively, these separate
studies fulfil the criteria of specificity and strengthen evidence
for the role of anti-angiogenic factors as the likely candidates
for the pre-eclampsia.
Several studies have attempted to show that inflammation
itself causes the clinical signs of pre-eclampsia. For example,
Faas et al. [88] showed that infusion of a single dose of
endotoxin to pregnant rats caused glomerular damage in
the kidney, as well as hypertension and proteinuria. In
addition, Hayakawa et al. [62], who developed an animal
model of immune-mediated abortion and pre-eclampsia due
to excessive activation of Th1/Th2 lymphocyte, showed that
in vitro-activated splenocytes with IL-12 and IL-4 injected
into pregnant mice induced hypertension, proteinuria and
histological renal changes, but not in controls. In a more
recent study, Zenclussen et al. [89] showed that activated
Th1-like cells, but not Th2-like cells, injected into mice led
to elevated blood pressure, proteinuria and kidney damage
exclusively in pregnant mice [89]. In support of these
studies, other groups have reported that immunosuppression
or inhibition of the inflammatory network improves the
aforementioned pathological conditions.
Indeed, in a ratmodel of pregnancy-induced hypertension,
as described previously [90], pharmacological immunosup-
pression of lymphocytes improved blood pressure and
endothelial function [91,92], indicating that prevention of T-
cell proliferationmay decrease hypertension. In amore recent
study, Zhou et al. [93] showed that injection of angiotensin-
II type I receptor-agonistic autoantibodies induced pre-
eclampsia-like features in mice and the inhibition of IL-6
in these mice inhibited these signs. Despite these studies,
the proposal that pre-eclampsia is primarily an inflammatory
disorder is somewhat at odds with clinical experience of the
use of corticosteroids used to accelerate fetal lungmaturation.
A prospective double-blind randomized clinical trial of
24 mg of betamethasone given as two 12 mg doses 24 h
apart and repeated weekly confirmed the known beneficial
effects of this treatment on neonatal outcome, but failed to
show any beneficial effect to the mother [94]. This dose
of betamethasone is equivalent to 160 mg of prednisolone,
which would be regarded as a huge dose of corticosteroid
and which would be expected to have major effects in other
inflammatory conditions. Moreover, in a similar clinical trial,
dexamethasone failed to improve the outcomeofwomenwith
HELLP syndrome [95].
Coherence and plausibility criteria
According to the Hill’s criteria of causation, the association
needs to be compatible with existing knowledge. The biology
of VEGF helps to validate the role of the anti-angiogenic
factor sFlt-1 as a cause of pre-eclampsia. VEGF is critical
for endothelial cells homoeostasis [96] and plays a crucial
role in the health of fenestrated and sinusoidal endothelium
found in the renal glomerulus, brain and liver [97], organs that
are severely compromised in pre-eclampsia. VEGF activates
both VEGFR (VEGF receptor)-1 and VEGFR-2 to stimulate
NO required for angiogenesis [30,31,98–102], which suggests
its beneficial role in the regulation of vascular tone and
blood pressure [103]. Indeed, exogenously administered
VEGF was shown to ameliorate post-cyclosporine-mediated
hypertension, endothelial dysfunction and nephropathy
[104,105]. Beneficial effects of VEGF have also been
observed in animal models of kidney disease [106–108].
Furthermore, cancer patients receiving anti-VEGF therapy
[22] or rats treatedwith VEGF-neutralizing antibody or sFlt-
1 [109] exhibit pre-eclampsia-like symptoms, indicating that
reduction in VEGF bioavailability is the likely initiator of
vascular damage responsible for the main clinical signs of
pre-eclampsia.
Increases in inflammatory cytokine production have been
associated with endothelial dysfunction, increased placenta
apoptosis, decreased angiogenesis and kidney abnormalities
that are relevant to the pathophysiology of pre-eclampsia
[110]. Endothelial cell damage induces the production of
ET-1 (endothelin-1) [111,112]. In pregnant mice, ET-1 was
shown to cause hypertension, proteinuria and renal damage.
Furthermore, IL-6 acts downstream of TNFα to induce the
release of ET-1 in mice. In addition, in the presence of
autoantibodies from pre-eclamptic women, IL-6 mediates
the release of ET-1 from human placental villous explants
[93]. These studies validate the original in vitro observations
of Collino et al. [113], which showed that pre-eclamptic
sera induces nephrin shedding from podocytes through ET-
1 release by endothelial glomerular cells. These separate
studies show an association between inflammation and ET-1
in rodents, and ET-1 may play an important role in pre-
eclampsia, but pregnant women with excessive inflammation
and high levels of inflammatory cytokines, such as those with
infections, do not always develop pre-eclampsia.
Conclusion
Collectively, the studies are important in elucidating the
sequence of events involved in the progression of pre-
eclampsia and its clinical signs (Figure 1). There is no doubt
that both angiogenic imbalance and systemic inflammation
are elevated in pre-eclampsia. However, on the basis of
the evidence and arguments made above, we advocate that
inflammation is a consequence rather than a cause of pre-
eclampsia. The most essential criterion of Bradford–Hill
is the principle of temporality, which states that when
a factor is believed to cause a disease, the factor must
necessarily always precede the occurrence of the disease.
The absence of temporality between the elevation in the
circulating inflammatorymarkers and the development of the
maternal syndrome of pre-eclampsia challenges the concept
that excessive inflammation is the cause of pre-eclampsia. In
contrast, the increase in circulating anti-angiogenic factors,
which precedes the clinical signs of pre-eclampsia, fulfils
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Figure 1 Progression of pregnancy to pre-eclampsia
A schematic diagram of the sequence of events along gestational age leading to the clinical signs of pre-eclampsia. EC,
endothelial cell; HO-1, haem oxygenase 1; TGF-β, transforming growth factor β.
the condition of temporality. Another crucial criterion is
the dose–response relationship, where increasing the level of
exposure to a factor increases the incidence and severity of the
disease. Although such a relationship has not been established
between pro-inflammatory cytokines and pre-eclampsia,
high levels of anti-angiogenic factors have been shown to
correlate with increased incidence of the disorder and disease
severity, hence satisfying this condition. Furthermore, Hill’s
experiment criterion states that removal of the cause by
an appropriate experimental regimen should ameliorate the
condition. Indeed, compelling evidence supporting a role for
anti-angiogenic factors as the leading cause of pre-eclampsia
has recently been shown in a clinical study, where removal
of circulating sFlt-1 from pre-eclamptic patients significantly
improved the clinical outcome [87]. In contrast, treatment
with high doses of corticosteroids failed to ameliorate
the maternal outcome in pre-eclampsia despite suppressing
inflammation.
Although inflammation may not be the cause of pre-
eclampsia, it may enhance the pathology of the disorder
in the presence of the anti-angiogenic factors. A recent
study demonstrated that sFlt-1 act synergistically with
pro-inflammatory mediators to activate endothelial cells
compared with endothelial cells treated with TNFα alone
[114]. Treatment with sFlt-1 or VEGF-neutralizing anti-
bodies or blockade of VEGFR-1 and VEGFR-2 reduced
the phosphorylation of Akt and eNOS leading to reduced
NO bioavailability and increased endothelial dysfunction
[114]. Furthermore, a recent study demonstrated that
adenoviral overexpression of sFlt-1 in endothelial cells
resulted in substantial inhibition of eNOS phosphorylation
and NO production as well as a decrease in VEGFR-
2 phosphorylation in pre-eclamptic placenta [27]. These
separate results provide additional support for the original
hypothesis put forward by Ahmed in 1997 [9] that lack
of VEGF and NO bioavailability is responsible for the
endothelial dysfunction in pre-eclampsia.
Whereas inflammation itself may not be the leading
cause of pre-eclampsia, it should also be recognized
that pregnant women with risk factors associated with
chronic inflammation (obesity, pre-pregnancy hypertension,
diabetes mellitus and dyslipidaemia) are more likely to
develop pre-eclampsia [115–118]. Furthermore, patients with
autoimmune diseases, particularly systemic lupus eryth-
aematosus and antiphospholipid syndrome, have increased
risks of developing pre-eclampsia [119,120]. The possibility
that inflammatory mediators may have local autocrine or
paracrine effects, which can lead to amplification of the anti-
angiogenic factors’ effects, cannot be ruled out at this stage.
In conclusion, we hypothesize that inflammation is not a
major contributor in the development of pre-eclampsia. In the
interest of finding an effective treatment, our focus should be
to target development of therapies based on the angiogenic
[28,121] and cytoprotective [3] theories, which seem more
promising.
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